Plate Nº 29 · recorded October 10, 2026
Health & Medicine ResearchReported finding
Nearly 17% of Children on GLP-1 Drugs Develop Nutritional Deficiencies
Nearly 17% of children prescribed GLP-1 drugs for weight loss or diabetes developed a nutritional deficiency within a year, a new study found. Vitamin D was the most common diagnosis.
By Nathan Brooks3 min read666 words
In brief
- 16.8% of children aged 10-17 on GLP-1 drugs developed a nutritional deficiency within 1 year of starting treatment
- Vitamin D deficiency affected 12.4% of children within a year of beginning GLP-1 therapy
- Only 5% of patients received nutritional counseling within 30 days of starting treatment
- Liraglutide accounted for 78.6% of prescriptions in the 2,031-patient study
- Study published September 23, 2026 in the journal Childhood Obesity

Nearly 1 in 6 children prescribed GLP-1 medications for weight loss or diabetes developed a diagnosed nutritional deficiency within their first year of treatment, according to a study published September 23, 2026 in the journal Childhood Obesity.
The analysis covered 2,031 patients ages 10 to 17 who started a GLP-1 receptor agonist between 2017 and 2022. Researchers tracked each child for nutritional deficiency diagnoses over the following 12 months. By the end of that year, 16.8% had received at least one such diagnosis.
Vitamin D deficiency ranked first, affecting 12.4% of children within one year of beginning therapy. The researchers also flagged iron and calcium as nutrients of concern for adolescents, though the study measured only clinical diagnoses.
What does the study tell us about pediatric GLP-1 use?
GLP-1 receptor agonists are medications that affect appetite and food intake. In this study, doctors prescribed them to children for weight loss, prediabetes, or type 2 diabetes. Among the 2,031 patients, liraglutide (sold as Victoza and Saxenda) accounted for 78.6% of prescriptions. Dulaglutide (Trulicity) made up 10.4%. Semaglutide (Ozempic and Wegovy) accounted for 9.1%.
Why are adolescents especially at risk?
Senior author Justin Ryder, PhD, of Ann & Robert H. Lurie Children's Hospital of Chicago, pointed to adolescence as a uniquely vulnerable window for nutritional problems.
"As appropriate pediatric use of GLP-1s becomes more widespread, we need to understand the risks during periods of rapid growth and pubertal development," Ryder said. "Nutrients such as vitamin D, iron and calcium are of particular concern during adolescence, when deficiencies may have lasting implications for skeletal health and overall development."
Adolescent bones accumulate mass rapidly. Iron supports blood volume expansion and cognitive function. A shortfall during this period can leave effects that stretch into adulthood.
How could these drugs lead to deficiencies?
Because GLP-1 medications affect appetite and food intake, children taking them may eat less and absorb fewer vitamins and minerals as a result. The study did not measure dietary intake directly, so researchers cannot say how much of the deficiency signal comes from reduced eating versus other mechanisms. The findings rely on clinical diagnoses recorded in insurance claims.
How often did children get nutritional counseling?
Rarely. Only 5% of patients received nutritional counseling within 30 days of starting a GLP-1. Fewer than 1 in 4 received counseling within six months. Ryder argues that this gap leaves young patients exposed during a treatment that often continues for years, and that nutritional support should begin alongside the prescription, not after a deficiency has already been diagnosed.
What do the researchers recommend?
Ryder's team argues that pediatricians should treat nutritional monitoring as part of the prescription, not a follow-up after problems appear.
"We hope that our study findings bring much needed recognition to the importance of proactive nutritional management when GLP-1s are prescribed to children, as opposed to waiting until a nutritional deficiency is diagnosed," Ryder said. "Knowing the risks, we are in a much better position to prevent harm to children treated with GLP-1s during a pivotal period in their lives."
The paper's authors include Kirk W. Kerr, Andrew T. Chang, Suela Sulo, John T. Stutts, Thadchaigeni Panchalingam, and Justin R. Ryder. It carries the DOI 10.1177/21532176261486979.
What are the study's limits?
The data come from administrative insurance claims, which capture diagnoses and prescriptions but not blood-test results, dietary surveys, or socioeconomic context. The analysis also cannot tell whether these children would have developed deficiencies without the medication.
The 16.8% figure reflects only diagnosed cases. Many mild deficiencies go undiagnosed, so the true rate could be higher. Conversely, children who get regular bloodwork may simply be more likely to catch deficiencies that others miss.
Still, the dataset — drawn from a claims database covering more than 100 million patients — gives the finding weight. For clinicians, the takeaway is concrete: screen early, counsel often, and watch the nutrient panel.
via dx.doi.org (Original)
More from Nathan Brooks
Nearby plates
- GLP-1 Diabetes Drugs Show Real-World Benefits in Young People
- GLP-1 Diabetes Drugs Appear Safe in Pregnancy, Review Finds
- Cleveland Clinic Examines What Happens After GLP-1 Discontinuation
- Stanford Medicine: 1 in 10 People May Resist GLP-1 Diabetes Drugs
- GLP-1 Weight-Loss Drugs Work Similarly Across Age, Race, and Weight